Cholangiocarcinoma Pipeline, FDA Approvals, Unmet Needs, Preclinical And Discovery Stage Product, And Companies 2024 (Updated)

(MENAFN- GetNews)

DelveInsight's,“ Cholangiocarcinoma Pipeline Insight 2024 ” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Cholangiocarcinoma Pipeline Report

• DelveInsight's Cholangiocarcinoma pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Cholangiocarcinoma treatment.
• The leading companies working in the Cholangiocarcinoma Market include
  Merck Sharp & dohme, Eisai, RedHill Biopharma Limited, TransThera Science, Kinnate Biopharma, Taiho Oncology, Bristol-Myers Squibb, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd., GlaxoSmithKline, Beijing InnoCare Pharma, Genoscience, 3D Medicines, Innovent Biologics (Suzhou) Co. Ltd., QED Therapeutics, Hutchison MediPharma, TriSalus Life Sciences, Relay Therapeutics, Eli Lilly and Company, Medivir, Boehringer Ingelheim, Compass Therapeutics, Intensity Therapeutics, Sirnaomics, Wellmarker Bio,
  and others.
• Promising Cholangiocarcinoma Pipeline Therapies in the various stages of development include
  Tinengotinib 8 mg, Ivosidenib, CX-4945, Cisplatin, Gemcitabine, E7090, Pemigatinib, and others.
• April 2024:- TransThera Sciences (Nanjing), Inc.- A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors. This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.

Request a sample and discover the recent advances in Cholangiocarcinoma Treatment Drugs @
Cholangiocarcinoma Pipeline Outlook Report

In the Cholangiocarcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cholangiocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Cholangiocarcinoma Overview

Cholangiocarcinoma is an epithelial cell malignancy arising from varying locations within the biliary tree and showing markers of cholangiocyte differentiation. The most contemporary classification based on anatomical location includes intrahepatic, perihilar, and distal cholangiocarcinoma. Many cases of cholangiocarcinoma arise de novo and do not have a specific risk factor, but there are a number of risk factors that have been identified, including primary hepatobiliary disease, genetic disorders, toxic exposures, and infections.

Find out more about Cholangiocarcinoma Therapeutics Assessment @
Cholangiocarcinoma Preclinical and Discovery Stage Products

Cholangiocarcinoma Emerging Drugs Profile

• Pembrolizumab: Merck Sharp & dohme
• E7090: Eisai
• ABC294640: RedHill Biopharma Limited
• TT-00420: TransThera Science
• KIN-3248: Kinnate Biopharma

Cholangiocarcinoma Pipeline Therapeutics Assessment

There are approx. 55+ key companies which are developing the Cholangiocarcinoma therapies. The Cholangiocarcinoma companies which have their Cholangiocarcinoma drug candidates in the most advanced stage, i.e. Phase III include, Merck Sharp & dohme.

DelveInsight's Cholangiocarcinoma pipeline report covers around
60+ products
under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Cholangiocarcinoma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Cholangiocarcinoma Pipeline Therapies @
Cholangiocarcinoma Clinical Trials Assessment

Scope of the Cholangiocarcinoma Pipeline Report

• Coverage- Global
• Cholangiocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cholangiocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Cholangiocarcinoma Companies- Merck Sharp & dohme, Eisai, RedHill Biopharma Limited, TransThera Science, Kinnate Biopharma, Taiho Oncology, Bristol-Myers Squibb, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd., GlaxoSmithKline, Beijing InnoCare Pharma, Genoscience, 3D Medicines, Innovent Biologics (Suzhou) Co. Ltd., QED Therapeutics, Hutchison MediPharma, TriSalus Life Sciences, Relay Therapeutics, Eli Lilly and Company, Medivir, Boehringer Ingelheim, Compass Therapeutics, Intensity Therapeutics, Sirnaomics, Wellmarker Bio, and others.
• Cholangiocarcinoma Pipeline Therapies- Tinengotinib 8 mg, Ivosidenib, CX-4945, Cisplatin, Gemcitabine, E7090, Pemigatinib, and others.

Dive deep into rich insights for new drugs for Cholangiocarcinoma Treatment, Visit @
Cholangiocarcinoma Market Drivers and Barriers, and Future Perspective

Table of Content